Information Provided By:
Fly News Breaks for July 30, 2019
Jul 30, 2019 | 07:31 EDT
Canaccord analyst Mark Massaro said Exact Sciences (EXAS) delivered a major preannounced Q2 beat and raise as well as a $2.8B buyout offer for Genomic Health (GHDX). The analyst said he is positive on the deal and does not see the prospects for any competing bids despite the shares closing above the deal price of $72 per share. Massaro raised his price target to $135 from $125 on Exact Sciences shares.
News For EXAS;GHDX From the Last 2 Days
There are no results for your query EXAS;GHDX